Bruton Tyrosine Kinase (BTK) May Be a Potential Therapeutic Target for Interstitial Cystitis/bladder Pain Syndrome

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2022 Sep 7

PMID 36069808

Authors

Guang Wang

Tong-Xin Yang

Jiong-Ming Li

Zi-Ye Huang

Wen-Bo Yang

Pei Li

Da-Lin He

Affiliations

Soon will be listed here.

Abstract

Aims: To determine the potential diagnostic and therapeutic targets of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).

Methods: We selected the GSE11783, GSE57560 and GSE621 datasets from the GEO database and merged them. R software was used to screen differentially expressed genes (DEGs) between IC/BPS and normal bladder tissues. The "String" online tool is used to analyze DEGs interaction and functional protein enrichment. CIBERSORT online tool was used to analyze the infiltration of immune cells. In addition, we verified the function of BTK in IC/BPS at the clinical samples and cells level.

Results: Bioinformatics analysis revealed that 5 genes were significantly overexpressed in IC/BPS, and the protein-protein interaction diagram showed that BTK was a critical link between these five proteins. At the same time, functional enrichment showed that they were significantly related to innate immunity. Immunoinfiltration showed that mast cell resting in IC/BPS was significantly higher. IHC staining of clinical samples showed that the mast cell markers Tryptase and BTK were highly expressed in IC/BPS tissues. At the cell level, knockdown of BTK inhibited proliferation, migration, invasion, and degranulation of mast cells.

Conclusions: This study provides a new perspective for understanding the molecular mechanisms involved in IC/BPS and suggests that BTK may be a target for treating IC/BPS.

Citing Articles

Identification and validation of immune and diagnostic biomarkers for interstitial cystitis/painful bladder syndrome by integrating bioinformatics and machine-learning.

Zhou T, Zhu C, Zhang W, Wu Q, Deng M, Jiang Z Front Immunol. 2025; 16:1511529.

PMID: 39917301 PMC: 11799275. DOI: 10.3389/fimmu.2025.1511529.

Emerging trends and research hotspots in the relationship between mast cells and atopic dermatitis based on the literature from 2001 to 2024: A bibliometric and visualized analysis.

Zuo W, Yue Z, Xu S, Sun C, Zou X, Ma J Skin Res Technol. 2024; 30(9):e70053.

PMID: 39234634 PMC: 11375331. DOI: 10.1111/srt.70053.

References

Wyndaele J, Riedl C, Taneja R, Lovasz S, Ueda T, Cervigni M . GAG replenishment therapy for bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2018; 38(2):535-544. DOI: 10.1002/nau.23900. View

Tanaka S . Phenotypic and Functional Diversity of Mast Cells. Int J Mol Sci. 2020; 21(11). PMC: 7312980. DOI: 10.3390/ijms21113835. View

Mohamed A, Yu L, Backesjo C, Vargas L, Faryal R, Aints A . Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009; 228(1):58-73. DOI: 10.1111/j.1600-065X.2008.00741.x. View

Chelimsky G, Heller E, Buffington C, Rackley R, Zhang D, Chelimsky T . Co-morbidities of interstitial cystitis. Front Neurosci. 2012; 6:114. PMC: 3415690. DOI: 10.3389/fnins.2012.00114. View

Sholan R . [Experimental evaluation of interaction of the nerve growth factor and mast cells in patients with interstitial cystitis/bladder pain syndrome]. Urologiia. 2020; (2):31-34. View

Jensen M, Jia W, Schults A, Ye X, Prestwich G, Oottamasathien S . IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis model. Cytokine. 2018; 110:420-427. PMC: 6103803. DOI: 10.1016/j.cyto.2018.05.012. View

Lemack G, Amundsen C, Badlani G, Griebling T, Peters K, Rodriguez L . Highlights from the combined Society of Urodynamics and Female Urology, and International Society of Pelvic Neuromodulation annual meeting. J Urol. 2007; 177(2):691-5. DOI: 10.1016/j.juro.2006.09.054. View

Petrosino S, Moriello A, Verde R, Allara M, Imperatore R, Ligresti A . Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity. J Neuroinflammation. 2019; 16(1):274. PMC: 6933707. DOI: 10.1186/s12974-019-1671-5. View

Fall M, Nordling J, Cervigni M, Oliveira P, Fariello J, Hanno P . Hunner lesion disease differs in diagnosis, treatment and outcome from bladder pain syndrome: an ESSIC working group report. Scand J Urol. 2020; 54(2):91-98. DOI: 10.1080/21681805.2020.1730948. View

10.

Sant G, Kempuraj D, Marchand J, Theoharides T . The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology. 2007; 69(4 Suppl):34-40. DOI: 10.1016/j.urology.2006.08.1109. View

11.

Mattsson P, Vihinen M, Smith C . X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease. Bioessays. 1996; 18(10):825-34. DOI: 10.1002/bies.950181009. View

12.

van de Merwe J, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha L . Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2007; 53(1):60-7. DOI: 10.1016/j.eururo.2007.09.019. View

13.

Zorn C, Simonowski A, Huber M . Stimulus strength determines the BTK-dependence of the SHIP1-deficient phenotype in IgE/antigen-triggered mast cells. Sci Rep. 2018; 8(1):15467. PMC: 6195619. DOI: 10.1038/s41598-018-33769-1. View

14.

Huang W, Morales J, Gazivoda V, August A . Nonreceptor tyrosine kinases ITK and BTK negatively regulate mast cell proinflammatory responses to lipopolysaccharide. J Allergy Clin Immunol. 2015; 137(4):1197-1205. PMC: 5730405. DOI: 10.1016/j.jaci.2015.08.056. View

15.

Aldenborg F, Fall M, Enerback L . Proliferation and transepithelial migration of mucosal mast cells in interstitial cystitis. Immunology. 1986; 58(3):411-6. PMC: 1453481. View

16.

Norman P . Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2016; 25(8):891-9. DOI: 10.1080/13543784.2016.1182499. View

17.

Dispenza M, Krier-Burris R, Chhiba K, Undem B, Robida P, Bochner B . Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. J Clin Invest. 2020; 130(9):4759-4770. PMC: 7456252. DOI: 10.1172/JCI138448. View

18.

Singh S, Dammeijer F, Hendriks R . Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018; 17(1):57. PMC: 5817726. DOI: 10.1186/s12943-018-0779-z. View

19.

Nilsson G, Butterfield J, Nilsson K, Siegbahn A . Stem cell factor is a chemotactic factor for human mast cells. J Immunol. 1994; 153(8):3717-23. View

20.

Gamperl S, Stefanzl G, Peter B, Smiljkovic D, Bauer K, Willmann M . Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. Vet Comp Oncol. 2019; 17(4):553-561. PMC: 6900099. DOI: 10.1111/vco.12520. View